Table 5.

Incidence of endometrial hyperplasia with unopposed estrogen or combination norethindrone acetate/estradiol therapy

	E2 1 mg	E2 1 mg/NETA 0.5 mg	E2 1 mg/NETA 0.25 mg	E2 1 mg/NETA 0.1 mg
Patients undergoing endometrial biopsy	247	241	251	249
Patients with endometrial hyperplasia	36 (14.6%)	1 (0.4%)*	1 (0.4%)*	2 (0.8%)*

^*p < 0.01